The Lewis lab research interests are focused on the development of new PET radiopharmaceuticals for the diagnosis and treatment of cancer. Our work incorporates 89Zr, 18F, 11C, and other nonstandard nuclides, with an emphasis on designing novel PET agents for cancer imaging. Our research program is a molecular-imaging-based program focused on the targeting of nonstandard nuclides as well as the development of small- and biomolecule-based agents and their clinical translation. A few examples of our work are given below.

Office phone:
Selected Achievements

Berson-Yalow Award, Society of Nuclear Medicine and Molecular Imaging (2013)

Jason Lewis

At Work: Radiochemistry Service Chief Jason Lewis

Radiochemist Jason Lewis works to develop new radiopharmaceuticals used in diagnosing and treating cancer.